

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wolf Bertling
Serial No. : 10/542,991
Filed : July 24, 2006
Title : MEDICAMENT AND USE THEREOF FOR TUMOR THERAPY

Art Unit : 1643
Examiner : Sheela Jitendra Huff
Conf. No. : 1187

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Information Disclosure Statement (1 page);
2. Form PTO-1449 (1 page);
3. Copies of cited references (6 references); and
4. A return postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

October 24, 2006

M. Angela Parsons, Ph.D.
Reg. No. 44,282

Fish & Richardson P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
(612) 335-5070 telephone
(612) 288-9696 facsimile

60390241.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 24, 2006

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wolf Bertling

Art Unit : 1643

Serial No. : 10/542,991

Examiner : Sheela Jitendra Huff

Filed : July 24, 2006

Conf. No. : 1187

Title : MEDICAMENT AND USE THEREOF FOR TUMOR THERAPY

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant requests consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. §1.98(a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. A copy of the listed U.S. patent application publication can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

October 24, 2006

M. Angela Parsons, Ph.D.

Reg. No. 44,282

Fish & Richardson P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696
60390208.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 24, 2006


Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./

Sheet 1 of 1Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17334-004US1Application No.
10/542,991**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

Applicant
Wolf BertlingFiling Date
July 24, 2006Group Art Unit
1643**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0192162	12/19/02	Green			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	195 41 284	05/30/96	DE			Abst.	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AC	Bleumer et al., "Immunotherapy for Renal Cell Carcinoma," <u>European Urology</u> , 2003, 44:65-75
	AD	Hill et al., "Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease," <u>Cancer Research</u> , 2002, 62:7254-7263
	AE	Ji et al., "Glycoinositol Phospholipid-anchored Interleukin 2 but not Secreted Interleukin 2 Inhibits Melanoma Tumor Growth in Mice," <u>Molecular Cancer Therapeutics</u> , 2002, 1:1019-1024
	AF	Terlikowski, "Local immunotherapy with rhTNF- α mutein induces strong antitumor activity without overt toxicity - a review," <u>Toxicology</u> , 2002, 174:143-152
	AG	Wong et al., " α -Interferon 2a and 13- <i>cis</i> -retinoic acid for the treatment of metastatic renal cell carcinoma," <u>Internal Medicine Journal</u> , 2002, 32:158-162

Examiner Signature

/Sheela Huff/

Date Considered

05/12/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./